Exposure–response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose‐ranging phase 2 trial

por Mukherjee, Arnab, Hazra, Anasuya, Smith, Mike K., Martin, Steven W., Mould, Diane R., Su, Chinyu, Niezychowski, Wojciech
Publicado 2018

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study

por Panés, Julián, D’Haens, Geert R., Higgins, Peter D. R., Mele, Linda, Moscariello, Michele, Chan, Gary, Wang, Wenjin, Niezychowski, Wojciech, Su, Chinyu, Maller, Eric
Publicado 2019

Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials

por Feagan, Brian G., Khanna, Reena, Sandborn, William J., Vermeire, Séverine, Reinisch, Walter, Su, Chinyu, Salese, Leonardo, Fan, Haiyun, Paulissen, Jerome, Woodworth, Deborah A., Niezychowski, Wojciech, Sands, Bruce E.
Publicado 2021

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

por Panés, Julian, Sandborn, William J, Schreiber, Stefan, Sands, Bruce E, Vermeire, Séverine, D'Haens, Geert, Panaccione, Remo, Higgins, Peter D R, Colombel, Jean-Frederic, Feagan, Brian G, Chan, Gary, Moscariello, Michele, Wang, Wenjin, Niezychowski, Wojciech, Marren, Amy, Healey, Paul, Maller, Eric
Publicado 2017